Celldex Therapeutics (Nasdaq:CLDX) - Aandelenkoers, Nieuws & Analyse

CLDX Overzicht aandelen

Celldex Therapeutics, Inc. is een biofarmaceutisch bedrijf dat zich bezighoudt met de ontwikkeling van therapeutische monoklonale en bispecifieke antilichamen voor de behandeling van verschillende ziekten. Meer informatie

CLDX fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 74.83% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Celldex Therapeutics, Inc. Concurrenten

Fusion Pharmaceuticals

NasdaqGS:FUSN

US$1.8b

Nurix Therapeutics

NasdaqGM:NRIX

US$1.6b

Deciphera Pharmaceuticals

NasdaqGS:DCPH

US$2.2b

Twist Bioscience

NasdaqGS:TWST

US$2.5b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Celldex Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$27.02
52 Week Hoogtepunt	US$53.18
52 Week Laag	US$22.93
Bèta	1.59
11 maand verandering	-5.76%
3 maanden verandering	-27.31%
1 Jaar Verandering	-5.76%
33 jaar verandering	-31.78%
5 jaar verandering	1,025.83%
Verandering sinds IPO	-76.39%

Recent nieuws en updates

Recent updates

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jun 05

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jul 07

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Apr 21

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Feb 27

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

May 25

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Feb 03

Celldex: Pipeline Of Drug Candidates Is Worth A Look

Feb 01

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

Sep 23

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Sep 15

Rendement voor aandeelhouders

	CLDX	US Biotechs	US Markt
7D	14.7%	2.4%	2.2%
1Y	-5.8%	16.2%	31.7%

Rendement versus industrie: CLDX presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 16.2 % opleverde.

Rendement versus markt: CLDX presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.7 % opleverde.

Prijsvolatiliteit

Is CLDX's price volatile compared to industry and market?
CLDX volatility
CLDX Average Weekly Movement	8.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: CLDX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van CLDX is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1983	160	Anthony Marucci	www.celldex.com

Celldex Therapeutics, Inc, een biofarmaceutisch bedrijf, houdt zich bezig met de ontwikkeling van therapeutische monoklonale en bispecifieke antilichamen voor de behandeling van verschillende ziekten. Haar kandidaat-geneesmiddelen omvatten therapeutica op basis van antilichamen voor de behandeling van patiënten met ontstekings-, allergische, auto-immuun- en andere verwoestende ziekten. De klinische ontwikkelingsprogramma's van het bedrijf zijn CDX-0159, een Fase II monoklonaal antilichaam dat bindt aan het receptortyrosinekinase KIT en de activiteit ervan remt.

Celldex Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Celldex Therapeutics zich tot de beurswaarde?
CLDX fundamentele statistieken
Marktkapitalisatie	US$1.74b
Inkomsten(TTM)	-US$154.08m
Inkomsten(TTM)	US$9.98m

179.7x

P/S-verhouding

-11.6x

Koers/Winstverhouding

Is CLDX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CLDX resultatenrekening (TTM)
Inkomsten	US$9.98m
Kosten van inkomsten	US$147.04m
Brutowinst	-US$137.06m
Overige uitgaven	US$17.02m
Inkomsten	-US$154.08m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.32
Brutomarge	-1,373.91%
Nettowinstmarge	-1,544.48%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde CLDX op de lange termijn?

Bekijk historische prestaties en vergelijking

CLDX Overzicht aandelen

Beloningen

Risicoanalyse

Celldex Therapeutics, Inc. Concurrenten

NasdaqGS:FUSN

US$1.8b

NasdaqGM:NRIX

US$1.6b

NasdaqGS:DCPH

US$2.2b

NasdaqGS:TWST

US$2.5b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought US$308k worth of stock

Consensus revenue estimates increase by 65%

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

Recent updates

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought US$308k worth of stock

Consensus revenue estimates increase by 65%

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 65%, EPS downgraded

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Price target decreased by 7.6% to US$65.38

Senior VP & Chief Medical Officer recently sold US$1.6m worth of stock

Chief Commercial Officer & Senior VP notifies of intention to sell stock

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024

Senior VP recently sold US$341k worth of stock

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Consensus revenue estimates decrease by 20%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Price target increased by 9.7% to US$69.43

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.475 million.

Consensus revenue estimates increase by 37%, EPS downgraded

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Price target increased by 7.4% to US$64.00

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023

Price target decreased by 7.4% to US$59.57

Consensus revenue estimates decrease by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Celldex Therapeutics, Inc. Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of Cdx-585 in Patients with Advanced Malignancies

Now 20% undervalued after recent price drop

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622

Consensus revenue estimates increase by 68%, EPS downgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Now 23% undervalued

Consensus revenue estimates increase by 11%, EPS downgraded

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors